SynthesisJournal of cosmetic dermatology2025
Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study.
Synthesis in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation. Hitherto, no network meta-analysis has investigated the relative effect of vitiligo on relevant monotherapies.
aimThe current study determined the relative effect of monotherapies for vitiligo through network meta-analyses (NMAs).
methodsThe peer-reviewed literature was systematically searched through PubMed and Scopus; studies that were eligible for quantitative analyses were those that were published in English and had an arm that investigated the effect of a monotherapy on vitiligo at 6 months. Studies of the randomized and observational designs were included.
resultsThe retrieved data were sufficient to analyze networks for phototherapy, Janus kinase inhibitors (JAKIs), calcineurin inhibitors, cyclosporine, corticosteroids, azathioprine, and minocycline. Modalities' effects, in each of the networks, were ranked with the surface under the cumulative ranking curve (SUCRA) metric; league tables were produced to depict agents' pairwise relative effects. Our secondary outcome was discontinuation due to any adverse event (AE) at 6 months.
conclusionsNo significant differences are observed among JAK inhibitors; however, upadacitinib, cyclosporine, ritlecitinib, and dexamethasone are significantly more effective than minocycline. Psoralen (oral) + ultraviolet A (PUVA) and narrow band ultraviolet B (NB-UVB) regimens show similar efficacy for repigmentation. Ruxolitinib 1.5% cream (once or twice daily), ruxolitinib 0.5% cream once daily, and ruxolitinib 0.15% cream once daily for 6 months do not differ significantly in efficacy. Mometasone furoate and tacrolimus 0.1% ointment are more effective than tacrolimus 0.03%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.